A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Pre-menopausal Breast CancerPI3K Pathway Inhibition
- Interventions
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02058381
- Locations
- 🇹🇭
Novartis Investigative Site, Chiang Mai, Thailand
Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT02058108
- Locations
- 🇺🇦
Novartis Investigative Site, Vinnytsia, Ukraine
Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 222
- Registration Number
- NCT02055352
- Locations
- 🇵🇦
Novartis Investigative Site, Panama City, Panamá, Panama
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: LFX453 H1Drug: LFX453 L1Drug: LFX453 H2Drug: LFX453 L2Drug: Placebo 1Drug: Placebo 2
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT02052687
- Locations
- 🇬🇧
Novartis Investigative Site, Mid Glamorgan, United Kingdom
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Phase 1
Completed
- Conditions
- Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT02051751
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
🇺🇸Horizon Oncology Center BioAdvance, Lafayette, Indiana, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02049450
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT02048787
- Locations
- 🇷🇴
Novartis Investigative Site, Bucuresti, Romania
To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension
Phase 1
Terminated
- Conditions
- Part 1 - Healthy VolunteersPart 2 - Patients With Hypertension
- Interventions
- Drug: Placebo to LFF269
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 93
- Registration Number
- NCT02047656
- Locations
- 🇺🇸
Novartis Investigative Site, Miami, Florida, United States
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02044848
- Locations
- 🇺🇸
Novartis Investigative Site, Seattle, Washington, United States
Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT02042014
- Locations
- 🇯🇵
Novartis Investigative Site, Mitaka-city, Tokyo, Japan